- Home
- UPXI vs WINT Comparison
UPXI vs WINT Comparison
Compare UPXI & WINT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UPXI
- WINT
- Stock Information
- Founded
- UPXI 2018
- WINT 1992
- Country
- UPXI United States
- WINT United States
- Employees
- UPXI N/A
- WINT N/A
- Industry
- UPXI Medicinal Chemicals and Botanical Products
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UPXI Health Care
- WINT Health Care
- Exchange
- UPXI Nasdaq
- WINT Nasdaq
- Market Cap
- UPXI 5.3M
- WINT 5.3M
- IPO Year
- UPXI 2021
- WINT 1995
- Fundamental
- Price
- UPXI $4.10
- WINT $0.48
- Analyst Decision
- UPXI Hold
- WINT Hold
- Analyst Count
- UPXI 1
- WINT 1
- Target Price
- UPXI $25.00
- WINT $18.00
- AVG Volume (30 Days)
- UPXI 2.5M
- WINT 1.9M
- Earning Date
- UPXI 11-22-2024
- WINT 11-26-2024
- Dividend Yield
- UPXI N/A
- WINT N/A
- EPS Growth
- UPXI N/A
- WINT N/A
- EPS
- UPXI N/A
- WINT N/A
- Revenue
- UPXI $83,980,115.00
- WINT N/A
- Revenue This Year
- UPXI $18.98
- WINT N/A
- Revenue Next Year
- UPXI $8.09
- WINT N/A
- P/E Ratio
- UPXI N/A
- WINT N/A
- Revenue Growth
- UPXI 27.11
- WINT N/A
- 52 Week Low
- UPXI $2.17
- WINT $0.45
- 52 Week High
- UPXI $33.00
- WINT $22.32
- Technical
- Relative Strength Index (RSI)
- UPXI 42.27
- WINT 24.83
- Support Level
- UPXI $4.52
- WINT $0.53
- Resistance Level
- UPXI $5.94
- WINT $0.64
- Average True Range (ATR)
- UPXI 1.42
- WINT 0.07
- MACD
- UPXI -0.34
- WINT 0.08
- Stochastic Oscillator
- UPXI 0.58
- WINT 6.24
About UPXI Upexi Inc.
Upexi Inc is an innovator in aggregation, accelerating Amazon and eCommerce businesses by combining consumer data and vertical integration to scale brands in multiple industries, while lowering costs with a growing distribution network.
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.